Big Data a $4 Billion opportunity in the healthcare & pharmaceutical industry, says SNS Research report

DUBAI, UAE. 7th August 2017:  SNS Research's latest report indicates that Big Data investments in the healthcare and pharmaceutical industry are expected to reach nearly $4 Billion by the end of 2017.

Originally used as a term to describe datasets whose size is beyond the ability of traditional databases, the scope of Big Data has significantly expanded over the years. Big Data not only refers to the data itself but also a set of technologies that capture, store, manage and analyze large and variable collections of data, to solve complex problems.

Amid the proliferation of real-time and historical data from sources such as connected devices, web, social media, sensors, log files and transactional applications, Big Data is rapidly gaining traction from a diverse range of vertical sectors. The healthcare and pharmaceutical industry is no exception to this trend, where Big Data has found a host of applications ranging from drug discovery and precision medicine to clinical decision support and population health management.

SNS Research estimates that Big Data investments in the healthcare and pharmaceutical industry will account for nearly $4 Billion in 2017 alone.  Led by a plethora of business opportunities for healthcare providers, insurers, payers, government agencies, pharmaceutical companies and other stakeholders, these investments are further expected to grow at a CAGR of more than 15% over the next three years.

The “Big Data in the Healthcare & Pharmaceutical Industry: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of Big Data in the healthcare and pharmaceutical industry including key market drivers, challenges, investment potential, application areas, use cases, future roadmap, value chain, case studies, vendor profiles and strategies. The report also presents market size forecasts for Big Data hardware, software and professional services investments from 2017 through to 2030. The forecasts are segmented for 8 horizontal submarkets, 5 application areas, 36 use cases, 6 regions and 35 countries.

The research publication will be of value to current and future potential investors into the Big Data sector, as well as Big Data vendors, healthcare providers, insurers, payers, pharmaceutical companies and other stakeholders who wish to broaden their knowledge of the ecosystem. 

For further information concerning the SNS Research publication "
Big Data in the Healthcare & Pharmaceutical Industry: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts" please visit: http://www.snstelecom.com/bigdatahealthcare

For a sample please contact:
Email: info@snstelecom.com

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to info@snstelecom.com

About SNS Research
SNS Research is one of the most foremost market intelligence and consulting firms for the worldwide telecommunications industry, with a particular focus on wireless infrastructure and mobile devices. Developed by leading industry analysts our market intelligence and consultancy services provide unique insights to the global telecommunications industry with information ranging from niche details of mobile handset models to tracking to large network infrastructure contracts and cellular network operator metrics. Whether your focus is strategic decision making, service development, investment or marketing, our services will allow you to make optimal decisions with self-assurance.
Comments